Literature DB >> 10598795

Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors.

H Prast1, M H Tran, H Fischer, M Kraus, C Lamberti, K Grass, A Philippu.   

Abstract

To investigate whether histaminergic neurons influence the activity of cholinergic neurons, the ventral striatum was superfused through a push-pull cannula and the release of endogenous acetylcholine was determined in the superfusate. Local inhibition of histamine synthesis by superfusion with alpha-fluoromethylhistidine (FMH) gradually decreased the release rate of acetylcholine. Superfusion with histamine increased the release of acetylcholine. The releasing effect of histamine was greatly inhibited when the striatum was simultaneously superfused with the D2/D3 agonist quinpirole and the D1 antagonist (+/-)-7-bromo-1-(fluoresceinylthioureido)phenyl-8-hydroxy-3-methyl -2,3,4,5-tetrahydro-1H-3-benzapine (SKF 83566). The effect of histamine on acetylcholine release was abolished by the GABA(A) receptor antagonist bicuculline. Superfusion with the H3 receptor agonists imetit or immepip increased acetylcholine release rate in the striatum. The releasing effects of the two H3 agonists were FMH resistant, while superfusion with quinpirole and SKF 83566 abolished the H3 receptor agonist-induced acetylcholine release. Superfusion with the H3 receptor antagonist thioperamide enhanced acetylcholine release rate. The releasing effect of thioperamide was abolished after inhibition of histamine synthesis by FMH. The release of acetylcholine by thioperamide was also abolished on simultaneous superfusion with quinpirole and SKF 83566. The findings show that, in the striatum, the activity of cholinergic neurons is permanently modulated by neighbouring histaminergic nerve terminals and axons. The release of acetylcholine is also permanently inhibited by neighbouring GABAergic neurons. The enhanced release of acetylcholine by the H3 receptor agonists imetit and immepip is due to stimulation of H3 heteroreceptors, while the increase of acetylcholine release by the H3 receptor antagonist thioperamide is elicited via blockade of H3 autoreceptors. Histamine released from histaminergic nerve terminals increases the release of acetylcholine in part by inhibition of dopamine release which, in turn, decreases GABAergic transmission. A dopamine-independent way seems also to be involved in the histamine-evoked acetylcholine release.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598795     DOI: 10.1007/s002109900097

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

1.  Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices.

Authors:  J A Arias-Montaño; B Floran; M Garcia; J Aceves; J M Young
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 3.  Neuronal histamine and the memory of emotionally salient events.

Authors:  Gustavo Provensi; Maria Beatrice Passani; Alessia Costa; Ivan Izquierdo; Patrizio Blandina
Journal:  Br J Pharmacol       Date:  2018-09-18       Impact factor: 8.739

Review 4.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

Review 5.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

6.  Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.

Authors:  S Ashworth; A Berges; E A Rabiner; A A Wilson; R A Comley; R Y K Lai; R Boardley; G Searle; R N Gunn; M Laruelle; V J Cunningham
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

7.  Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum.

Authors:  Ricardo Márquez-Gómez; Meridith T Robins; Citlaly Gutiérrez-Rodelo; Juan-Manuel Arias; Jesús-Alberto Olivares-Reyes; Richard M van Rijn; José-Antonio Arias-Montaño
Journal:  Pharmacol Res       Date:  2017-12-05       Impact factor: 7.658

8.  Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET.

Authors:  Pablo Rusjan; Pamela Sabioni; Patricia Di Ciano; Esmaeil Mansouri; Isabelle Boileau; Alexia Laveillé; Marc Capet; Thierry Duvauchelle; Jean-Charles Schwartz; Philippe Robert; Bernard Le Foll
Journal:  Br J Pharmacol       Date:  2020-05-23       Impact factor: 8.739

9.  Influence of the hippocampus on amino acid utilizing and cholinergic neurons within the nucleus accumbens is promoted by histamine via H₁ receptors.

Authors:  M M Kraus; H Prast; A Philippu
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

10.  Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata.

Authors:  Sarah Threlfell; Stephanie J Cragg; Imre Kalló; Gergely F Turi; Clive W Coen; Susan A Greenfield
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.